REPATHA 140 mg, solution injectable en stylo prérempli

USDailyMed:Evolocumab AU:B1 C10AX13(WHO) AU:S4(Prescription only)CA:℞-onlyUS:℞-onlyEU:Rx-onlyIn general: ℞ (Prescription only) 1256937-27-5 none LKC0U3A8NJ D10557Y Evolocumab,sold under the brand nameRepatha, is amonoclonal antibodythat is animm​​​‍​​‍​​​​‍​​‍‍unotherapymedication for the treatment ofhyperlipidemia. Evolocumab is a fully human monoclonal antibody that inhibitsproprotein convertase subtilisin/kexin type 9 (PCSK9). PCSK9 is a protein that targetsLDL receptorsfor degradation; its inhibition thereby enhances theliver's ability to removeLDL-C, often colloquially referred to as "bad"cholesterol, from the blood. In 2023, it was the 188th most commonly prescribed medication in the United States, with more than 2 million prescriptions.